Targeted therapeutics
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
1. A process of producing SDC-TRAP-0063 Sodium
or its tautomer comprising the steps of:
1). dissolving SDC-TRAP-0063 in tert-butanol at 25-35° C.;
2). adding 0.3 normal aqueous sodium hydroxide and Water for Injection to adjust pH to be above around 9.8;
3). filtering the mixture from step 2). with at least two 0.2 μm filters in series; and
4). conducting aseptic vial filling and lyophilization.